DLX1 and neoplasm: To investigate the efficacy of BETi against DLX1-mediated tumor growth in vivo, we implanted 22RV1 cells subcutaneously in athymic immunodeficient mice, and when the tumors reached a palpable stage (average volume ~75 mm3); mice were randomized into four groups (n = 6) and the drugs were administered.